Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference Transcript

Jun 16, 2022 / 03:40PM GMT
Release Date Price: $46.78 (-2.48%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone. Thanks for joining us. We're really pleased to have the Blueprint Medicines Company with us. We have Kate Haviland, CEO; and Becker Hewes, CMO.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, Kate, to start here, how is Blueprint evolving under new leadership? Have there been any surprises that you've -- as you've stepped into the CEO role, any changes to strategy?

Kathryn Haviland
Blueprint Medicines Corporation - President, CEO & Director

Yes. So first of all, Salveen, thank you for having us here. We really appreciate the opportunity, and we appreciate Goldman Sachs inviting us for this event. So really, no, I mean I think one of the great benefits of the leadership kind of succession and evolution at Blueprint is that the opportunity for myself and other members of our team to really -- who have been with the company for multiple years and have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot